Targeted Oncology presents Precision Medicine, a video series featuring oncology experts discussing how to use a more customized approach when treating patients with cancer.
July 14th 2021
A discussion ofJAK2-directed therapies, their roles in treatment, and the key clinical trials guiding their use in myeloproliferative neoplasms. Also discussed are some relevant data recently presented at ASCO.
May 20th 2021
Jason M. Melear, MD, and Ian W. Flinn, MD, PhD, discuss the role of PI3K inhibitors in the management of R/R follicular lymphoma and marginal zone lymphoma.
April 23rd 2021
Experts discuss advances in gastrointestinal stromal tumors (GIST) and dive into the evolving landscape and ongoing unmet needs.
March 30th 2021
Experts in genitourinary oncology discuss emerging research surrounding the clinical utility of phenotypic biomarkers, such as prostate-specific membrane antigen (PSMA), for use in the treatment of metastatic castration-resistant prostate cancer.
March 30th 2021
A panel discusses the role of TKI combination therapies for patients with advanced renal cell carcinoma and how they have changed the treatment landscape.
January 19th 2021
A review of key relevant data on HER2-positive breast cancer from the 2020 SABCS Virtual Symposium.
December 23rd 2020
Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.
November 5th 2020
An in-depth discussion on the targeting of specific molecular pathways with newer, novel therapies to better manage patients with liver cancer.
July 31st 2020
Experts from Sarah Cannon Research Institute talk about the expanding role of targeted treatment options in early HER2+ breast cancer.
July 28th 2020
A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.